Treatment of severe osteoporosis with alendronate in a patient with lysinuric protein intolerance

J Inherit Metab Dis. 2006 Oct;29(5):687. doi: 10.1007/s10545-006-0236-9. Epub 2006 Jul 25.

Abstract

Lysinuric protein intolerance is an inborn error of cationic amino acid transport of which osteoporosis is a major feature. Treatment with oral bisphosphonates improves bone mineral density even in severe osteoporosis.

Publication types

  • Case Reports

MeSH terms

  • Alendronate / pharmacology*
  • Amino Acid Metabolism, Inborn Errors / complications*
  • Amino Acid Metabolism, Inborn Errors / therapy*
  • Bone Density Conservation Agents / pharmacology
  • Humans
  • Lysine / chemistry*
  • Osteoporosis / complications*
  • Osteoporosis / therapy*

Substances

  • Bone Density Conservation Agents
  • Lysine
  • Alendronate